The results were confirmed by the PP analysis , with 54/66 ( 81.8 % ) cured patients in the linezolid group versus 52/59 ( 88.1 % ) in the trimethoprim/sulfamethoxazole and rifampicin group ( risk difference 6.3 % , 95 % CI -6.8 % to 19.2 % ) .